Skip to main content

FULC

Stock
Health Care
Biotechnology

Performance overview

FULC Price
Price Chart

Forward-looking statistics

Beta
1.56
Risk
90.62%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Company info

SectorHealth Care
IndustryBiotechnology
Employees100
Market cap$515.3M

Fundamentals

Enterprise value$152.9M
Revenue$80.0M
Revenue per employee—
Profit margin-0.64%
Debt to equity3.55

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.01
Dividend per share—
Revenue per share$1.29
Avg trading volume (30 day)$4M
Avg trading volume (10 day)$5M
Put-call ratio—

Macro factor sensitivity

Growth-0.1
Credit+2.3
Liquidity-2.1
Inflation-1.0
Commodities+1.4
Interest Rates-2.6

Valuation

Dividend yield0.00%
PEG Ratio-5.67
Price to sales4.67
P/E Ratio-5.67
Enterprise Value to Revenue1.91
Price to book1.63

Upcoming events

Next earnings dayMay 1, 2025
Next dividend day—
Ex. dividend day—

News

Fulcrum Therapeutics (FULC) Upgraded to Buy: Here's Why

Fulcrum Therapeutics (FULC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (November 28, 2024)
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease

BofA Securities has upgraded Fulcrum Therapeutics FULC ahead of the company's phase 3 losmapimod readout, expected by the end of October for Facioscapulohumeral muscular dystrophy (FSHD).

Benzinga (September 9, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free